Company intelligence / Profile preview

Ascentage Pharma

Suzhou, Jiangsu, Chinaascentagegroup.com ↗

Ownership: Private
Employees: ~567
Development stage: Other

Overview

Ascentage Pharma has advanced several small molecule inhibitors into clinical trials targeting apoptosis pathways for cancer and HBV. Their lead asset HQP1351 has reached next-generation kinase inhibitor status. Other key drugs include APG1252, APG2575, and APG115. The company has demonstrated strong progress with increasing revenue from novel therapies and global expansion of its pipeline.

Therapeutic areas: Infectious DiseasesOncologyOther
Modalities: Small molecule
Industry: Biotech

Partnerships

Takeda Pharmaceutical Company Limited holds a significant equity stake (~7%)

Beyond the preview

Go deeper on Ascentage Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascentage Pharma.

Explore the full profile